Live Breaking News & Updates on Ultragenyx Pharmaceutical Company Profile

Stay updated with breaking news from Ultragenyx pharmaceutical company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

JPMorgan Chase & Co. Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $88.00

JPMorgan Chase & Co. Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $88.00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Robertw Baird , Truist Financial Corp , Ultragenyx Pharmaceutical Company Profile , Deutsche Bank , Jpmorgan Chase Co , Wells Fargo Company , Manufacturers Life Insurance Company , Ultragenyx Pharmaceutical Inc , Cantor Fitzgerald , Charles Schwab Investment Management Inc , Canaccord Genuity Group , Ultragenyx Pharmaceutical , Get Free Report , Financial Corp , Schwab Investment Management , Pharmaceutical Inc , North America , Latin America , Ultragenyx Pharmaceutical Daily ,

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reaffirmed at Cantor Fitzgerald

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reaffirmed at Cantor Fitzgerald
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Piper Sandler , Robertw Baird , Us Bancorp , Morgan Stanley , Wells Fargo Company , Lazard Asset Management , Ultragenyx Pharmaceutical Inc , Cantor Fitzgerald , Ultragenyx Pharmaceutical Company Profile , Comerica Bank , Ultragenyx Pharmaceutical , Free Report , Moderate Buy , Get Free Report , Asset Management , Pharmaceutical Inc , North America , Latin America , Ultragenyx Pharmaceutical Daily ,

Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded by StockNews.com to "Hold"

StockNews.com upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) from a sell rating to a hold rating in a research report released on Friday. Other research analysts also recently issued research reports about the stock. Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an overweight […] ....

United States , Emild Kakkis , Piper Sandler , Thomas Richard Kassberg , American International Group Inc , Ultragenyx Pharmaceutical Inc , Securities Exchange Commission , Lazard Asset Management , Ultragenyx Pharmaceutical Company Profile , Morgan Stanley , Cantor Fitzgerald , Ultragenyx Pharmaceutical , Free Report , Moderate Buy , Get Free Report , Richard Kassberg , Exchange Commission , Asset Management , International Group , North Carolina , Arizona State Retirement System , State Retirement System , Pharmaceutical Inc , North America , Latin America , Ultragenyx Pharmaceutical Daily ,

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Buy" from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Buy" from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Piper Sandler , Emild Kakkis , Thomas Richard Kassberg , Ultragenyx Pharmaceutical Company Profile , Dimensional Fund Advisors , Wells Fargo Company , Morgan Stanley , Cantor Fitzgerald , Metlife Investment Management , Ultragenyx Pharmaceutical Inc , Raymond James Associates , Securities Exchange Commission , Us Bancorp , Ultragenyx Pharmaceutical , Get Free Report , Pharmaceutical Trading Down , Richard Kassberg , Exchange Commission , Montreal Can , Life Investment Management , Fund Advisors , Get Free , Pharmaceutical Inc , North America , Latin America ,

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) from a hold rating to a sell rating in a research note released on Wednesday. Other research analysts have also issued research reports about the company. Cantor Fitzgerald reissued an overweight rating and issued a $114.00 target price on shares of Ultragenyx Pharmaceutical in a […] ....

United States , Piper Sandler , Emild Kakkis , Thomas Richard Kassberg , Metlife Investment Management , Dimensional Fund Advisors , Ultragenyx Pharmaceutical Inc , Cantor Fitzgerald , Ultragenyx Pharmaceutical Company Profile , Us Bancorp , Morgan Stanley , Raymond James Associates , Ultragenyx Pharmaceutical , Free Report , Moderate Buy , Get Free Report , Richard Kassberg , Montreal Can , Life Investment Management , Fund Advisors , Pharmaceutical Inc , North America , Latin America , Ultragenyx Pharmaceutical Daily , Nasdaq Rare , Stocknews Com ,